These observations underline the intrinsic correlation between MYC and the DDR, and the importance of dual targeting of the DDR and BCL-2 in MYC/BCL-2 positive lymphoma in order to maximize the therapeutic efficacy. The gene discussed is BCL2; the disease is lymphoma.